Cargando…
Decentralized clinical trials (DCTs): A few ethical considerations
Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Con...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797802/ https://www.ncbi.nlm.nih.gov/pubmed/36590004 http://dx.doi.org/10.3389/fpubh.2022.1081150 |
_version_ | 1784860762215284736 |
---|---|
author | Petrini, Carlo Mannelli, Chiara Riva, Luciana Gainotti, Sabina Gussoni, Gualberto |
author_facet | Petrini, Carlo Mannelli, Chiara Riva, Luciana Gainotti, Sabina Gussoni, Gualberto |
author_sort | Petrini, Carlo |
collection | PubMed |
description | Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of digital tools such as e-consent, apps, wearable devices, Electronic Patient-Reported Outcomes (ePRO), telemedicine, as well as on moving trial activities to the patient's home (e.g., drug delivery) or to local healthcare settings (i.e., community-based diagnosis and care facilities). DCTs adapt to patients' routines, allow patients to participate regardless of where they live by removing logistical barriers, offer better access to the study and the investigational product, and permit the inclusion of more diverse and more representative populations. The feasibility and quality of DCTs depends on several requirements including dedicated infrastructures and staff, an adequate regulatory framework, and partnerships between research sites, patients and sponsors. The evaluation of Ethics Committees (ECs) is crucial to the process of innovating and digitalizing clinical trials: adequate assessment tools and a suitable regulatory framework are needed for evaluation by ECs. DCTs also raise issues, many of which are of considerable ethical significance. These include the implications for the relationship between patients and healthcare staff, for the social dimension of the patient, for data integrity (at the source, during transmission, in the analysis phase), for personal data protection, and for the possible risks to health and safety. Despite their considerable growth, DCTs have only received little attention from bioethicists. This paper offers a review on some ethical implications and requirements of DCTs in order to encourage further ethical reflection on this rapidly emerging field. |
format | Online Article Text |
id | pubmed-9797802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97978022022-12-30 Decentralized clinical trials (DCTs): A few ethical considerations Petrini, Carlo Mannelli, Chiara Riva, Luciana Gainotti, Sabina Gussoni, Gualberto Front Public Health Public Health Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of digital tools such as e-consent, apps, wearable devices, Electronic Patient-Reported Outcomes (ePRO), telemedicine, as well as on moving trial activities to the patient's home (e.g., drug delivery) or to local healthcare settings (i.e., community-based diagnosis and care facilities). DCTs adapt to patients' routines, allow patients to participate regardless of where they live by removing logistical barriers, offer better access to the study and the investigational product, and permit the inclusion of more diverse and more representative populations. The feasibility and quality of DCTs depends on several requirements including dedicated infrastructures and staff, an adequate regulatory framework, and partnerships between research sites, patients and sponsors. The evaluation of Ethics Committees (ECs) is crucial to the process of innovating and digitalizing clinical trials: adequate assessment tools and a suitable regulatory framework are needed for evaluation by ECs. DCTs also raise issues, many of which are of considerable ethical significance. These include the implications for the relationship between patients and healthcare staff, for the social dimension of the patient, for data integrity (at the source, during transmission, in the analysis phase), for personal data protection, and for the possible risks to health and safety. Despite their considerable growth, DCTs have only received little attention from bioethicists. This paper offers a review on some ethical implications and requirements of DCTs in order to encourage further ethical reflection on this rapidly emerging field. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797802/ /pubmed/36590004 http://dx.doi.org/10.3389/fpubh.2022.1081150 Text en Copyright © 2022 Petrini, Mannelli, Riva, Gainotti and Gussoni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Petrini, Carlo Mannelli, Chiara Riva, Luciana Gainotti, Sabina Gussoni, Gualberto Decentralized clinical trials (DCTs): A few ethical considerations |
title | Decentralized clinical trials (DCTs): A few ethical considerations |
title_full | Decentralized clinical trials (DCTs): A few ethical considerations |
title_fullStr | Decentralized clinical trials (DCTs): A few ethical considerations |
title_full_unstemmed | Decentralized clinical trials (DCTs): A few ethical considerations |
title_short | Decentralized clinical trials (DCTs): A few ethical considerations |
title_sort | decentralized clinical trials (dcts): a few ethical considerations |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797802/ https://www.ncbi.nlm.nih.gov/pubmed/36590004 http://dx.doi.org/10.3389/fpubh.2022.1081150 |
work_keys_str_mv | AT petrinicarlo decentralizedclinicaltrialsdctsafewethicalconsiderations AT mannellichiara decentralizedclinicaltrialsdctsafewethicalconsiderations AT rivaluciana decentralizedclinicaltrialsdctsafewethicalconsiderations AT gainottisabina decentralizedclinicaltrialsdctsafewethicalconsiderations AT gussonigualberto decentralizedclinicaltrialsdctsafewethicalconsiderations |